FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted
Adrián Vallejo, Oihane Erice, Rodrigo Entrialgo-Cadierno, Iker Feliu, Elizabeth Guruceaga, Maria J. Perugorria, Paula Olaizola, Alexandra Muggli, Irati Macaya, Michael O’Dell, Borja Ruiz-Fernandez de Cordoba, Sergio Ortiz-Espinosa, Aram F. Hezel, Imanol Arozarena, Fernando Lecanda, Matias A. Avila, Maite G. Fernández-Barrena, Matthias Evert, Mariano Ponz-Sarvise, Diego F. Calvisi, Jesus M. Banales, Silve VicentJournal of Hepatology2021
Background & Aims: Cholangiocarcinoma (CCA) is a neoplasia of the biliary tract driven by genetic, epigenetic and transcriptional mechanisms. Herein, we investigated the role of the transcrip- tion factor FOSL1, as well as its downstream transcriptional ef- fectors, in the development and progression of CCA. Methods: FOSL1 was investigated in human CCA clinical sam- ples. Genetic inhibition of FOSL1 in human and mouse CCA cell lines was performed in in vitro and in vivo models using constitutive and inducible short-hairpin RNAs. Conditional FOSL1 ablation was done using a genetically engineered mouse (GEM) model of CCA (mutant KRAS and Trp53 knockout). Follow- up RNA and chromatin immunoprecipitation (ChIP) sequencing analyses were carried out and downstream targets were vali- dated using genetic and pharmacological inhibition. Results: An inter-species analysis of FOSL1 in CCA was con- ducted. First, FOSL1 was found to be highly upregulated in hu- man and mouse CCA, and associated with poor patient survival. Pharmacological inhibition of different signalling pathways in CCA cells converged on the regulation of FOSL1 expression. Functional experiments showed that FOSL1 is required for cell proliferation and cell cycle progression in vitro, and for tumour growth and tumour maintenance in both orthotopic and sub- cutaneous xenograft models. Likewise, FOSL1 genetic abrogation in a GEM model of CCA extended mouse survival by decreasing the oncogenic potential of transformed cholangiocytes. RNA and ChIP sequencing studies identified direct and indirect tran- scriptional effectors such as HMGCS1 and AURKA, whose genetic and pharmacological inhibition phenocopied FOSL1 loss. Conclusions: Our data illustrate the functional and clinical relevance of FOSL1 in CCA and unveil potential targets amenable to pharmacological inhibition that could enable the imple- mentation of novel therapeutic strategies. Lay summary: Understanding the molecular mechanisms involved in cholangiocarcinoma (bile duct cancer) development and progression stands as a critical step for the development of novel therapies. Through an inter-species approach, this study provides evidence of the clinical and functional role of the transcription factor FOSL1 in cholangiocarcinoma. Moreover, we report that downstream effectors of FOSL1 are susceptible to pharmacological inhibition, thus providing new opportunities for therapeutic intervention.